Omeros (OMER) Competitors $3.00 -0.20 (-6.25%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OMER vs. ASMB, NKTR, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, and ZTSShould you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Assembly Biosciences (ASMB), Nektar Therapeutics (NKTR), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry. Omeros vs. Its Competitors Assembly Biosciences Nektar Therapeutics Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol Myers Squibb Zoetis Omeros (NASDAQ:OMER) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends. Do institutionals and insiders hold more shares of OMER or ASMB? 48.8% of Omeros shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 12.9% of Omeros shares are owned by company insiders. Comparatively, 5.1% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher earnings and valuation, OMER or ASMB? Assembly Biosciences has higher revenue and earnings than Omeros. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmerosN/AN/A-$156.82M-$2.65-1.13Assembly Biosciences$28.52M4.85-$40.18M-$6.23-2.91 Do analysts rate OMER or ASMB? Omeros currently has a consensus price target of $18.00, suggesting a potential upside of 500.00%. Assembly Biosciences has a consensus price target of $33.00, suggesting a potential upside of 82.12%. Given Omeros' stronger consensus rating and higher possible upside, research analysts clearly believe Omeros is more favorable than Assembly Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omeros 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83Assembly Biosciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is OMER or ASMB more profitable? Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -124.15%. Omeros' return on equity of 0.00% beat Assembly Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets OmerosN/A N/A -59.68% Assembly Biosciences -124.15%-131.77%-36.81% Does the media favor OMER or ASMB? In the previous week, Omeros had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 8 mentions for Omeros and 7 mentions for Assembly Biosciences. Omeros' average media sentiment score of 0.68 beat Assembly Biosciences' score of 0.20 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assembly Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, OMER or ASMB? Omeros has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. SummaryOmeros beats Assembly Biosciences on 13 of the 16 factors compared between the two stocks. Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMER vs. The Competition Export to ExcelMetricOmerosMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$187.50M$10.35B$5.45B$8.90BDividend YieldN/A2.10%5.36%4.13%P/E Ratio-1.1317.2826.4419.67Price / SalesN/A28.36405.31110.28Price / CashN/A23.5625.8827.49Price / Book-0.953.657.925.42Net Income-$156.82M$233.36M$3.15B$248.34M7 Day Performance-11.24%1.43%0.62%0.81%1 Month Performance-3.54%3.03%4.94%5.01%1 Year Performance-24.05%-11.77%32.27%18.10% Omeros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMEROmeros3.6637 of 5 stars$3.00-6.3%$18.00+500.0%-26.1%$187.50MN/A-1.13210Analyst ForecastASMBAssembly Biosciences3.626 of 5 stars$17.10-1.7%$33.00+93.0%+32.1%$130.64M$28.52M-2.74100News CoverageGap UpHigh Trading VolumeNKTRNektar Therapeutics4.5928 of 5 stars$9.54+12.1%$67.50+607.5%+38.9%$118.39M$98.43M-0.99220Gap UpHigh Trading VolumeCPIXCumberland Pharmaceuticals0.7018 of 5 stars$3.93-9.7%N/A+119.0%$58.79M$37.87M-15.7280Trending NewsLLYEli Lilly and Company4.9823 of 5 stars$770.16+1.0%$1,011.79+31.4%-13.9%$729.91B$45.04B62.6747,000Positive NewsAnalyst DowngradeJNJJohnson & Johnson4.9565 of 5 stars$151.33+1.0%$170.88+12.9%+4.4%$364.11B$88.82B16.83138,100Positive NewsABBVAbbVie4.9351 of 5 stars$183.92-0.7%$211.29+14.9%+8.3%$324.88B$56.33B78.2655,000Trending NewsMRKMerck & Co., Inc.4.9963 of 5 stars$80.15+1.4%$109.19+36.2%-36.0%$201.26B$64.17B11.6775,000Positive NewsPFEPfizer4.8635 of 5 stars$24.04+0.3%$29.17+21.3%-13.3%$136.68B$63.63B17.4281,000Positive NewsDividend AnnouncementBMYBristol Myers Squibb4.9852 of 5 stars$46.97+0.2%$58.00+23.5%+11.6%$95.59B$48.30B17.5934,100Positive NewsZTSZoetis4.8073 of 5 stars$157.51+0.2%$212.13+34.7%-10.1%$70.12B$9.29B28.2813,800Positive News Related Companies and Tools Related Companies ASMB Alternatives NKTR Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives MRK Alternatives PFE Alternatives BMY Alternatives ZTS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OMER) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Omeros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
